Josemar Faustino, Douglas Oliveira, T. Fernandes, P. Simioni
{"title":"类风湿性关节炎的生物治疗:主要已批准单克隆抗体的综述","authors":"Josemar Faustino, Douglas Oliveira, T. Fernandes, P. Simioni","doi":"10.5455/ww.53482","DOIUrl":null,"url":null,"abstract":"Introduction Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that has a high destructive potential throughout its progression. The disease evolution generates significant social and economic costs. 1–3 This is a multifactorial and systemic disease of unknown etiology, which can mainly affect the joints, evolving with joint destruction and deformity, often becoming incapacitating. 4,5 Abstract","PeriodicalId":201249,"journal":{"name":"Worldwide Medicine","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biological treatment for rheumatoid arthritis: a review of the main approved monoclonal antibodies\",\"authors\":\"Josemar Faustino, Douglas Oliveira, T. Fernandes, P. Simioni\",\"doi\":\"10.5455/ww.53482\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that has a high destructive potential throughout its progression. The disease evolution generates significant social and economic costs. 1–3 This is a multifactorial and systemic disease of unknown etiology, which can mainly affect the joints, evolving with joint destruction and deformity, often becoming incapacitating. 4,5 Abstract\",\"PeriodicalId\":201249,\"journal\":{\"name\":\"Worldwide Medicine\",\"volume\":\"20 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Worldwide Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/ww.53482\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Worldwide Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/ww.53482","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Biological treatment for rheumatoid arthritis: a review of the main approved monoclonal antibodies
Introduction Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that has a high destructive potential throughout its progression. The disease evolution generates significant social and economic costs. 1–3 This is a multifactorial and systemic disease of unknown etiology, which can mainly affect the joints, evolving with joint destruction and deformity, often becoming incapacitating. 4,5 Abstract